Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07326709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Study acronym: INVEST-HD
StatusRecruiting
PhasePhase 3
Started2026-03-24
View on ClinicalTrials.gov ↗

Amendment history

2026-08-28
Study Status, Contacts/Locations v17
Trial sites expanded: 82 → 117 locations
Trial sites expanded: 60 → 82 locations
2026-08-10
Study Status, Contacts/Locations v16
Trial sites expanded: 51 → 60 locations
2026-07-28
Study Status, Contacts/Locations v15
Trial sites expanded: 41 → 51 locations
2026-07-09
Study Status, Contacts/Locations v14
Trial sites expanded: 27 → 41 locations
2026-06-19
Study Status, Contacts/Locations v13
Trial sites expanded: 24 → 27 locations
Trial sites expanded: 20 → 24 locations
2026-06-17
Study Status, Contacts/Locations v12
Study sites20→24
2026-06-05
Study Status, Contacts/Locations v11
Trial sites expanded: 13 → 20 locations
2026-05-25
Study Status, Contacts/Locations v10
Study sites11→13
2026-05-20
Study Status, Contacts/Locations v9
Study sites10→11
2026-05-12
Study Status, Contacts/Locations v8
Study sites10 entries, revised
NovartisNorth InvestigativeYork SiteGeneral Hospital
2026-05-11
Study Status v7
Re-verified, no change to tracked fields
2026-04-29
Study Status, Contacts/Locations v6
Trial sites expanded: 4 → 10 locations
2026-04-15
Study Status, Contacts/Locations v5
Study sites4 entries, revised
NovartisCentre Investigativede Siterecherche du CHUM
2026-04-13
Study Status, Contacts/Locations v4
Study sites2→4
2026-03-26
Study Status v3
Start dateestimated 2026-06-01→confirmed 2026-03-24
2026-03-19
Study Status, Contacts/Locations v2
Study sites1→2
2026-03-11
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites0→1
2026-01-07
Original filing
Novartis
552 trials monitored
See 32 trials at risk
Huntington's Disease
78 trials monitored
See 3 trials at risk
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Trial Details
NCT Number NCT07326709
Lead Sponsor Novartis Pharmaceuticals
Conditions Huntington Disease
Enrollment 770 participants
Start Date 2026-03-24
Primary Completion 2030-04-02 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-22